Similar articles

• Mycoplasma pneumoniae Community Acquired Respiratory Distress Syndrome toxin expression reveals growth phase and infection-dependent regulation.

  Kannan TR, Musatovova O, Balasubramanian S, Cagle M, Jordan JL, Krunkosky TM, Davis A, Hardy RD, Baseman JB. Kannan TR, et al. Mol Microbiol. 2010 Jun 1;76(5):1127-41. doi: 10.1111/j.1365-2958.2010.07092.x. Epub 2010 Feb 28. Mol Microbiol. 2010. PMID: 20199607 Free PMC article.
• Macrolides in asthma.

  Medford ARL. Medford ARL. Chest. 2012 Feb;141(2):569-570. doi: 10.1378/chest.11-2364. Chest. 2012. PMID: 22315126 No abstract available.
• Exploring the pathogenicity of Mycoplasma pneumoniae: Focus on community-acquired respiratory distress syndrome toxins.

  Xu N, Fan L, Li L, Guo Y. Xu N, et al. Microb Pathog. 2024 Oct;195:106865. doi: 10.1016/j.micpath.2024.106865. Epub 2024 Aug 15. Microb Pathog. 2024. PMID: 39153578 Review.
• Vaccine using community-acquired respiratory distress syndrome toxin as an antigen against Mycoplasma pneumoniae in mice.

  Yoshikawa E, Tamiya S, Inoue Y, Suzuki K, Yoshioka Y. Yoshikawa E, et al. Biochem Biophys Res Commun. 2022 Feb 26;594:81-87. doi: 10.1016/j.bbrc.2022.01.058. Epub 2022 Jan 19. Biochem Biophys Res Commun. 2022. PMID: 35078111
• Pathogenesis of Mycoplasma pneumoniae: An update.

  Chaudhry R, Ghosh A, Chandolia A. Chaudhry R, et al. Indian J Med Microbiol. 2016 Jan-Mar;34(1):7-16. doi: 10.4103/0255-0857.174112. Indian J Med Microbiol. 2016. PMID: 26776112 Review.